Saturday 17 October 2026
Export BCRX’s income statement to Excel — free account
BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
7.79
0.23
−2.87%
Follow BCRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 6.24 | 0.00 | 0.00 |
P/S ratio |
2.66 | 1.87 | 2.60 | 2.71 | |
P/FCF ratio |
33.33 | 4.74 | 7.42 | 6.81 | |
P/Operating CF |
38.32 | 5.61 | (37.32) | 24.39 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.43 | 2.11 | 3.30 | 3.22 | |
EV/EBITDA |
28.78 | 5.45 | 0.00 | 0.00 | |
EV/Operating CF |
40.93 | 5.31 | 9.35 | 8.06 | |
EV/FCF |
42.94 | 5.34 | 9.41 | 8.11 | |
Quick Ratio |
1.60 | 1.95 | 1.78 | 2.22 | |
Current Ratio |
1.87 | 2.06 | 1.91 | 2.32 | |
Net Debt/EBITDA |
16.28 | 0.79 | (0.89) | 4.92 | |
Debt/Assets |
150.73% | 93.53% | 184.94% | 150.47% | |
Debt/Equity |
(1.73) | (4.04) | (1.55) | (1.85) | |
Asset Turnover |
1.28 | 1.74 | 1.87 | 1.85 | |
Operating CF/Net income |
3.23 | 1.19 | 0.09 | 1.33 | |
Capex/Depreciation |
0.98 | 0.36 | (0.28) | (0.70) | |
Interest Coverage |
1.51 | 18.42 | (35.47) | 4.54 | |
Research and Development Expense of Revenue |
27.98% | 10.05% | 38.56% | 23.81% | |
Selling, General and Administrative Expense of Revenue |
52.08% | 23.56% | 60.45% | 29.31% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.67% | 5.85% | 10.25% | 6.73% | |
Graham Net Nets |
(0.30) | (0.14) | (0.28) | (0.21) | |
Graham Number |
1.44 | 0.00 | 9.43 | 7.61 | |
Earnings Yield |
(0.66%) | 16.03% | (18.17%) | (14.40%) | |
Free Cash Flow Yield |
3.00% | 21.10% | 13.48% | 14.69% | |
Revenue per Share |
0.76 | 1.94 | 0.65 | 0.86 | |
Operating CF per Share |
0.20 | 1.39 | (0.26) | 0.41 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.19 | 1.39 | (0.26) | 0.41 | |
Cash per Share |
1.02 | 1.31 | 0.99 | 1.39 | |
Shareholders Equity per Share |
(1.85) | (0.57) | (2.29) | (1.79) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.85) | (0.57) | (2.29) | (1.79) | |
Free Cash Flow |
40.28 | 291.71 | (62.19) | 104.13 | |
Working Capital |
165.45 | 208.28 | 178.23 | 275.84 | |
Capital Expenditures |
(1.34) | (0.25) | (0.40) | (0.21) | |
Net Current Asset Value |
(478.63) | (228.96) | (645.27) | (527.46) | |
EV/EBIT |
27.00 | 5.41 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
20.96 | 4.80 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
81.89 | 92.94 | 101.33 | 100.97 | |
Average Payables |
9.52 | 13.74 | 10.50 | 10.02 | |
Average Inventory |
6.40 | 6.74 | 6.43 | 5.55 | |
Average Assets |
468.84 | 502.29 | 472.55 | 507.52 | |
Average Common Equity |
(428.23) | (297.54) | (502.88) | (437.94) |
Columns are period end dates